[go: up one dir, main page]

PE20020903A1 - Metodo para prevenir la diarrea - Google Patents

Metodo para prevenir la diarrea

Info

Publication number
PE20020903A1
PE20020903A1 PE2001000284A PE2001000284A PE20020903A1 PE 20020903 A1 PE20020903 A1 PE 20020903A1 PE 2001000284 A PE2001000284 A PE 2001000284A PE 2001000284 A PE2001000284 A PE 2001000284A PE 20020903 A1 PE20020903 A1 PE 20020903A1
Authority
PE
Peru
Prior art keywords
octreotide
irinotecan
administration
refers
prevent diarrhea
Prior art date
Application number
PE2001000284A
Other languages
English (en)
Inventor
Langdon Miller
John David Rothermel
Hugh Michael O'down
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20020903A1 publication Critical patent/PE20020903A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN METODO PARA PREVENIR LA DIARREA CAUSADA POR LA ADMINISTRACION DE IRINOTECAN O UNA SAL O UN METABOLITO FARMACEUTICAMENTE ACEPTABLE QUE COMPRENDE ADMINISTRAR A UN PACIENTE UNA CANTIDAD EFECTIVA DE UN OCTREOTIDO EN FORMA DE SAL ACETATO. EL OCTREOTIDO SE FORMULA EN UNA FORMA DE DOSIFICACION DE LIBERACION CON ACCION PROLONGADA. SE REFIERE TAMBIEN A FORMULACIONES DE COMBINACION Y A KITS PARA PREVENIR LA DIARREA PROVOCADA POR EL IRINOTECAN O LA ADMINISTRACION DE UN ANALOGO DE CAMPTOTECINA
PE2001000284A 1999-11-29 2001-03-27 Metodo para prevenir la diarrea PE20020903A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/450,201 US6159935A (en) 1999-11-29 1999-11-29 Method for preventing diarrhea

Publications (1)

Publication Number Publication Date
PE20020903A1 true PE20020903A1 (es) 2002-10-23

Family

ID=23787180

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000284A PE20020903A1 (es) 1999-11-29 2001-03-27 Metodo para prevenir la diarrea

Country Status (6)

Country Link
US (2) US6159935A (es)
AR (1) AR026606A1 (es)
AU (1) AU3439301A (es)
CO (1) CO5271647A1 (es)
PE (1) PE20020903A1 (es)
WO (1) WO2001037784A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060205681A1 (en) * 2002-06-21 2006-09-14 Maryam Moaddeb Homogenous paste formulations
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
PT1787658E (pt) 2005-11-10 2012-06-22 Chemi Spa Formulações de libertação sustentada de análogos de somatostatina inibidores da hormona do crescimento
AU2009294320B2 (en) 2008-09-17 2015-04-16 Amryt Endo, Inc. Pharmaceutical compositions and related methods of delivery
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
MA43800A (fr) * 2016-01-21 2021-05-12 Chiasma Inc Octréotide par voie orale pour le traitement de maladies
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19375086I2 (de) * 1979-11-27 2003-01-09 Novartis Ag Polypeptide Verfahren zu ihrer Herstellung pharmazeutische Zusammensetzungen die diese Polypeptide enthalten und ihre Verwendung
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5789411A (en) 1995-09-11 1998-08-04 Lance L. Gooberman P. C. Improvements to rapid opioid detoxification
US5919760A (en) 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
BR9807271A (pt) * 1997-02-27 2000-05-23 Pharmacia & Upjohn Spa Tamoxifeno como terapia para reduzir diarréia induzida por cloridrato de irinotecano

Also Published As

Publication number Publication date
US6159935A (en) 2000-12-12
WO2001037784A2 (en) 2001-05-31
US6395708B1 (en) 2002-05-28
AU3439301A (en) 2001-06-04
AR026606A1 (es) 2003-02-19
CO5271647A1 (es) 2003-04-30
WO2001037784A3 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
BR0115382A (pt) Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
AR022254A1 (es) Composicion de administracion oral.
ECSP034620A (es) Mezclas o compuestos organicos para el tratamiento de enfermedades de las vias respiratorias
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
CO4970819A1 (es) Tratamiento de disfuncion sexual femenina en una hembra humana
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
AR015919A1 (es) Formas de dosificacion de liberacion sostenida de sertralina, sales de sertralina ,composicion farmaceutica, procedimiento depreparacion y su uso en terapias.
DK383987D0 (da) Ny galeniske formuleringer med programmeret afgivelse indeholdende antiphlogistika
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
MXPA04003608A (es) Composiciones inyectables para el suministro controlado de compuesto farmacologicamente activo.
CO5280073A1 (es) Composiciones
AR033688A1 (es) Composicion parenteral reconstituible
PE20010480A1 (es) PRODUCTOS DE DROGAS ß-CARBOLINE
SV2002000036A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
BR0114100A (pt) Formulações de liberação controlada para administração oral
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal